Drugs / JHM03
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06584240 | Sep 2024 → May 2025 | — | JHM BioPharma (Tonghua) Co. , Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT06199336 | Jan → Sep 2024 | — | JHM BioPharma (Tonghua) Co. , Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JHM03 | “Recombinant Botulinum Toxin Type A (JHM03)” NCT06584240 ↗ |
| Known as | Recombinant Botulinum Toxin Type A | “Recombinant Botulinum Toxin Type A (JHM03)” NCT06584240 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Botulinum Toxin Type A” NCT06584240 ↗ |
| Route | Intramuscular | “intramuscularly injected” NCT06584240 ↗ |